XTL Biopharmaceuticals Ltd. (TLV:XTLB)
2.700
0.00 (0.00%)
At close: Jan 30, 2026
XTL Biopharmaceuticals Revenue
XTL Biopharmaceuticals had revenue of $258.50K USD in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $968.00K. In the year 2024, XTL Biopharmaceuticals had annual revenue of $451.00K.
Revenue (ttm)
$968.00K
Revenue Growth
n/a
P/S Ratio
7.83
Revenue / Employee
$96.80K
Employees
10
Market Cap
25.55M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 451.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 42.17M |
| Evogene | 26.54M |
| Can-Fite BioPharma | 1.89M |
| Clal Biotechnology Industries | 91.00K |
| Geffen Residence & Renewal | 84.00K |
| BioLight Life Sciences | 21.00K |
XTL Biopharmaceuticals News
- 2 days ago - XTL Update on Recent Developments - GlobeNewsWire
- 8 days ago - XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - GlobeNewsWire
- 19 days ago - XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership - GlobeNewsWire
- 19 days ago - XTL Biopharmaceuticals To Acquire 85% Stake In NeuroNOS Ltd For $32.5 Mln - Nasdaq
- 19 days ago - Beyond Air (XAIR) Moves NeuroNOS to XTL Biopharmaceuticals Through Acquisition Deal - GuruFocus
- 5 weeks ago - XTL Biopharmaceuticals receives Nasdaq bid price deficiency notice - Seeking Alpha
- 5 weeks ago - XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency - GlobeNewsWire
- 10 months ago - XTL Names Mr. Noam Band as its New Chief Executive Officer - GlobeNewsWire